TheEdgeResearch
Home / Stocks / THNR

Amplify Weight Loss Drug & Treatment ETF (THNR)

AMEX Financial Services Asset Management
$26.50 ▼ -0.40%
Market Cap
$5.3M
Sector
Financial Services
Industry
Asset Management
Beta
0.38
52-Wk Range
22.33-27.28
CEO
Country
US
Currency
USD

Amplify Weight Loss Drug & Treatment ETF operates in the Asset Management industry of the Financial Services sector, headquartered in Lisle, IL, US. The stock last traded at $26.50, down 0.40% on the session, giving a market capitalisation of $5.3M. Its beta of 0.38 implies it has historically moved less than the broad market.

Company profile
Exchange
New York Stock Exchange Arca
Employees
IPO date
2024-05-21
Headquarters
Lisle, IL, US
About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.

Comparable companies

Amplify Weight Loss Drug & Treatment ETF is most often compared with the following Financial Services names:

BEDZCDIGCREDDUKXEAFGEATZGENDIONKPROMCHS
More research on THNR
THNR technical analysis THNR TheEdge Score Compare against peers
Open full interactive analysis & DCF →